EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy of Biological or Targeted Synthetic Disease‐Modifying Anti‐Rheumatic Drugs in Active Psoriatic Arthritis: A Network Meta‐Analysis of Randomized Controlled Trials

Siming Gao, Hui Song

Journal of Clinical Pharmacy and Therapeutics · 2025-01 · 2025 (1)

DOI: 10.1155/jcpt/6541156 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Pharmacy and Therapeutics, online erschienen am 28.03.2025. Verfasst von Siming Gao und 1 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Many biological or targeted synthetic disease‐modifying anti‐rheumatic drugs (b/ts DMARDs) are used in the treatment of psoriatic arthritis (PsA) during recent years, but there are few head‐to‐head studies that directly compare these drugs to evaluate and compare the relative efficacy of these treatments at week 24. The aim of this study is to conduct a comprehensive comparison of all clinically used bDMARDs or tsDMARDs for PSA using a network meta‐analysis to evaluate relative efficacy of these drugs, which is evaluated by ACR20, ACR50, ACR70, PASI75, and PASI90.

Methods

All randomized controlled trials of these treatments are searched in PubMed, Web of Science, and Embase, and data are extracted from the included articles, and network meta‐analysis is performed using the Stata 13 software. Results: secukinumab 300 mg is the top‐ranked treatment for ACR20 and PASI90, infliximab 5 mg/kg is the top‐ranked treatment for ACR50, and adalimumab 40 mg is the top‐ranked treatment for ACR70 and PASI75.

Conclusions

Tumor necrosis factor‐α inhibitors and interleukin 17A inhibitors are the top‐ranked treatments for arthritis and skin responses of active PsA.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Gao, S., & Song, H. (2025). Efficacy of Biological or Targeted Synthetic Disease‐Modifying Anti‐Rheumatic Drugs in Active Psoriatic Arthritis: A Network Meta‐Analysis of Randomized Controlled Trials. Journal of Clinical Pharmacy and Therapeutics, 2025(1). https://doi.org/10.1155/jcpt/6541156

Vancouver

Gao S, Song H. Efficacy of Biological or Targeted Synthetic Disease‐Modifying Anti‐Rheumatic Drugs in Active Psoriatic Arthritis: A Network Meta‐Analysis of Randomized Controlled Trials. Journal of Clinical Pharmacy and Therapeutics. 2025;2025(1). doi:10.1155/jcpt/6541156

BibTeX
@article{Gao2025,
  author = {Gao, Siming and Song, Hui},
  title = {Efficacy of Biological or Targeted Synthetic Disease‐Modifying Anti‐Rheumatic Drugs in Active Psoriatic Arthritis: A Network Meta‐Analysis of Randomized Controlled Trials},
  journal = {Journal of Clinical Pharmacy and Therapeutics},
  year = {2025},
  volume = {2025},
  number = {1},
  doi = {10.1155/jcpt/6541156}
}
Kostenlos starten →